Delving into the Latest Updates on Influenza A vaccine intranasal(Altimmune, Inc.) with Synapse

Overview

Basic Info

Drug Type

Prophylactic vaccine

Synonyms

Influenza A vaccine H5N1, Influenza A vaccine intranasal, Influenza-virus-vaccine-Vaxin

+ [3]

Target-

Mechanism

Immunostimulants

Therapeutic Areas

Infectious DiseasesRespiratory Diseases

Active Indication-

Inactive Indication

COVID-19Influenza, Human

Originator Organization

Altimmune, Inc.

Active Organization-

Inactive Organization

Altimmune, Inc.

Drug Highest PhaseDiscontinuedPhase 2

First Approval Date-

Regulation-

Login to view timeline

BACKGROUNDAdjuvant System 03 (AS03) markedly enhances responses to influenza A/H5N1 vaccines, but the mechanisms of this enhancement are incompletely understood.METHODSUsing ribonucleic acid sequencing on peripheral blood mononuclear cells (PBMCs) from AS03-adjuvanted and unadjuvanted inactivated H5N1 vaccine recipients, we identified differentially expressed genes, enriched pathways, and genes that correlated with serologic responses. We compared bulk PBMC findings with our previously published assessments of flow-sorted immune cell types.RESULTSAS03-adjuvanted vaccine induced the strongest differential signals on day 1 postvaccination, activating multiple innate immune pathways including interferon and JAK-STAT signaling, Fcγ receptor (FcγR)-mediated phagocytosis, and antigen processing and presentation. Changes in signal transduction and immunoglobulin genes predicted peak hemagglutinin inhibition (HAI) titers. Compared with individual immune cell types, activated PBMC genes and pathways were most similar to innate immune cells. However, several pathways were unique to PBMCs, and several pathways identified in individual cell types were absent in PBMCs.CONCLUSIONSTranscriptomic analysis of PBMCs after AS03-adjuvanted H5N1 vaccination revealed early activation of innate immune signaling, including a 5- to 8-fold upregulation of FcγR1A/1B/1C genes. Several early gene responses were correlated with HAI titer, indicating links with the adaptive immune response. Although PBMCs and cell-specific results shared key innate immune signals, unique signals were identified by both approaches.

15 Sep 2017·The Journal of Infectious DiseasesQ2 · MEDICINE

An Adjuvanted A(H5N1) Subvirion Vaccine Elicits Virus-Specific Antibody Response and Improves Protection Against Lethal Influenza Viral Challenge in Mouse Model of Protein Energy Malnutrition

Q2 · MEDICINE

Article

Author: Gangappa, Shivaprakash ; Jones, Enitra N ; Amoah, Samuel ; Sambhara, Suryaprakash ; Cao, Weiping

BackgroundProtein energy malnutrition (PEM) increases susceptibility to infectious diseases, including influenza infection, but no studies have addressed the potential influences of PEM on the immunogenicity and protective efficacy of avian influenza A(H5N1) vaccine.MethodsWe investigated the role of PEM on vaccine-mediated protection after a lethal challenge with recombinant A(H5N1) virus using isocaloric diets providing either adequate protein (AP; 18% protein) or very low protein (VLP; 2% protein) in an established murine model of influenza vaccination.ResultsWe demonstrated that mice maintained on a VLP diet succumb to lethal challenge at greater rates than mice maintained on an AP diet, despite comparable immunization regimens. Importantly, there was no virus-induced mortality in both VLP and AP groups of mice when either group was immunized with adjuvanted low-dose A(H5N1) subvirion vaccine.ConclusionsOur results suggest that adjuvanted vaccination in populations where PEM is endemic may be one strategy to boost vaccination-promoted immunity and improve outcomes associated with highly pathogenic A(H5N1).

100 Deals associated with Influenza A vaccine intranasal(Altimmune, Inc.)

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB15859

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
COVID-19	Phase 2	US	Altimmune, Inc.	10 Oct 2020
Influenza, Human	Phase 2	US	Altimmune, Inc.	18 Sep 2017

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04442230 (CTgov)	Phase 2	COVID-19	48	NasoVAX (NasoVAX)	injijhwqmv(lsaffhmgbf) = lubowpmmvb nawbnqcqzc (pjzoqemmoj, ndpwcmxogy - zgprfngwrh) View more	-	04 Apr 2022
				Placebo (Placebo)	injijhwqmv(lsaffhmgbf) = kwjsbduwkc nawbnqcqzc (pjzoqemmoj, rcmsdkyksk - fqgjlsykbd) View more
NCT03232567 (CTgov)	Phase 2	Influenza, Human	60	NasoVAX (NasoVAX Low Dose)	yqnialduvf(fgjkmfdsrr) = gwrawepfgm xzdsctbmtx (vpidskiyju, zzjfyfovsg - ardfsizupe) View more	-	11 Apr 2019
				NasoVAX (NasoVAX Medium Dose)	yqnialduvf(fgjkmfdsrr) = xcrzoeespc xzdsctbmtx (vpidskiyju, ugaftkrqiq - frclcwtqle) View more